Kaplan-Meier plots comparing OS for patients with DLBCL treated with EPOCH vs CHOP and R-EPOCH vs R-CHOP. (A) HIV-positive patients with newly diagnosed DLBCL treated with infusional EPOCH (dashed line) achieved significantly longer OS than patients treated with CHOP (solid line; P = .016). (B) This was also seen when the analysis was limited to patients with DLBCL treated in the rituximab era, where treatment with R-EPOCH (dashed line) compared favorably to treatment with R-CHOP (solid line; P = .087).